<DOC>
	<DOCNO>NCT01451411</DOCNO>
	<brief_summary>The objective study evaluate efficacy , safety pharmacokinetics intravenous conivaptan pediatric subject abnormally low concentration sodium blood .</brief_summary>
	<brief_title>A Study Assess Efficacy , Safety Pharmacokinetics Intravenous Conivaptan ( Vaprisol® ) Pediatric Subjects With Euvolemic Hypervolemic Hyponatremia</brief_title>
	<detailed_description>A 3:1 randomization conivaptan placebo implement randomization stratify 1:1:2 ratio age group : 2-5 year , 6-10 year , 11-17 year . Subjects need remain hospitalized 48-hour Treatment Period Hour 96 ( Day 4 ) . There follow-up safety visit Day 9 day hospital discharge , whichever occur first . There final follow-up phone call Day 32 assess serious adverse event occur since hospital discharge .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Subject euvolemic hypervolemic hyponatremia upon clinical presentation Subject serum sodium value ≥ 115 mEq/L ( 115 mmol/L ) &lt; 130 mEq/L ( 130 mmol/L ) 24 hour precede inclusion study Female subject childbearing potential must negative serum pregnancy test must premenarchal , surgically sterile must practice method birth control Female subject pregnant lactating Subject body mass index ( BMI ) &lt; 3rd percentile &gt; 97th percentile age stature accord World Health Organization ; Body mass indexforage percentile chart boy girl age 2 20 Subject clinical evidence volume depletion , dehydration hypovolemia Subject hypovolemic hyponatremia transient cause hyponatremia likely resolve time study participation Subjects cause hyponatremia appropriately correct alternative therapy Subject expect receive emergent treatment hyponatremia treatment period study Subject clinical evidence hypotension Subject uncontrolled hypertension &gt; 99th percentile age Subject uncontrolled bradyarrhythmias tachyarrhythmias require emergent pacemaker placement treatment Subject untreated severe hypothyroidism , hyperthyroidism adrenal insufficiency Subject know urinary outflow obstruction , unless subject , catheterized study Subject estimate creatinine clearance &lt; 30 mL/min seven day prior study drug administration Subject alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) elevation &gt; 3 time upper limit normal reference range seven day prior study drug administration Subject serum albumin ≤ 1.5 g/dL seven day prior study drug administration Subject white blood cell count ( WBC ) &lt; 3000/microliter documented time seven day prior study drug administration anticipate drop WBC &lt; 3000/microliter period study due chemotherapy Subject currently unstable hepatic function history hepatic encephalopathy , bleed esophageal varix within last 3 month Subject acute heart failure . Prior history heart failure allow current signs/symptoms Subject nonfasting blood glucose value ≥ 275 mg/dL Subject require suspected require treatment potent inhibitor potent inducer CYP3A4 Subject administer hypertonic saline oral salt supplement within 24 hour prior study drug administration Subject require use medication use treatment Syndrome Inappropriate Antidiuretic Hormone Secretion ( SIADH ) : include lithium salt , urea demeclocycline week prior screen throughout study drug treatment period Subject condition may interfere treatment evaluation safety Subject receive investigational therapy ( include placebo ) within 28 day 5 half life , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Serum Sodium</keyword>
	<keyword>Euvolemia</keyword>
	<keyword>Hypervolemia</keyword>
	<keyword>Vaprisol®</keyword>
	<keyword>Conivaptan</keyword>
	<keyword>YM087</keyword>
</DOC>